G764-0233 Screening compound: 5'-ETHYL-N-[2-(TRIFLUOROMETHYL)PHENYL]-5'H-SPIRO[PIPERIDINE-4,4'-PYRROLO[1,2-A]QUINOXALINE]-1-CARBOXAMIDE

G764-0233 Screening compound: 5'-ETHYL-N-[2-(TRIFLUOROMETHYL)PHENYL]-5'H-SPIRO[PIPERIDINE-4,4'-PYRROLO[1,2-A]QUINOXALINE]-1-CARBOXAMIDE
G764-0233 Screening compound: 5'-ETHYL-N-[2-(TRIFLUOROMETHYL)PHENYL]-5'H-SPIRO[PIPERIDINE-4,4'-PYRROLO[1,2-A]QUINOXALINE]-1-CARBOXAMIDE alternative view

Chemical Structure Depiction of ChemDiv screening compound G764-0233
5'-ETHYL-N-[2-(TRIFLUOROMETHYL)PHENYL]-5'H-SPIRO[PIPERIDINE-4,4'-PYRROLO[1,2-A]QUINOXALINE]-1-CARBOXAMIDE

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

G764-0233

Molecular Formula

C25H25F3N4O (C25 H25 F3 N4 O)

Compound Name

5'-ETHYL-N-[2-(TRIFLUOROMETHYL)PHENYL]-5'H-SPIRO[PIPERIDINE-4,4'-PYRROLO[1,2-A]QUINOXALINE]-1-CARBOXAMIDE

IUPAC name

5'-ethyl-N-[2-(trifluoromethyl)phenyl]-5'H-spiro[piperidine-44'-pyrrolo[12-a]quinoxaline]-1-carboxamide

SMILES

CCN(C1(CC2)CCN2C(Nc2c(C(F)(F)F)cccc2)=O)c(cccc2)c2-n2c1ccc2

InChI

InChI=1S/C25H25F3N4O/c1-2-32-21-11-6-5-10-20(21)31-15-7-12-22(31)24(32)13-16-30(17-14-24)23(33)29-19-9-4-3-8-18(19)25(26,27)28/h3-12,15H,2,13-14,16-17H2,1H3,(H,29,33)

InChI Key

UZJVUYCOPLYTTK-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD15034041

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

454.5

Hydrogen Bond Acceptors Count

2.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

5.00

Number of Nitrogen and Oxygen Atoms

5

Partition Coefficient, logP

5.732

Distribution Coefficient, logD

5.730

Water Solubility, LogSw

-5.40

Polar Surface Area

28.046

Acid Dissociation Constant (pKa)

13.79

Base Dissociation Constant (pKb)

5.00

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

32.00

G764-0233 in Drug Discovery

Included in Screening Libraries

3D-Biodiversity Library (27607 compounds)

Antiviral Annotated Library (21441 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Protein-Protein Interaction Library (218420 compounds)

Serine Proteases Inhibitors Library (32732 compounds)

Spiro Library (21655 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

ChemoGenomic Annotated Library for Phenotypic Screening (89798 compounds)

Target Identification, Phenotypic Screening library (TIPS) (27612 compounds)

Included in 1.7M Stock Database

Structure:
  • 3D
  • Cyclic compounds
  • Cyclic compounds
Mechanism of action:
  • PPI modulators
  • PPI modulators
Therapeutical areas:
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Cardiovascular
  • Skin
  • Metabolic
  • Immune system
Targets:
  • Proteases

References: we are preparing a list of scientific research reports with G764-0233 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound G764-0233?
Check Price and Availability of G764-0233, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of G764-0233 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for G764-0233
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for G764-0233
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of G764-0233 available by request